Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET-letter

Clinical Cancer Research

Volumn 19, Issue 15, 2013, Pages 4290-

  Rimassa, Lorenza ^a   Bruix, Jordi ^b   Broggini, Massimo ^c   Santoro, Armando ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ERLOTINIB; PLACEBO; SCATTER FACTOR RECEPTOR; TIVANTINIB; TUBULIN; 2 PYRROLIDONE DERIVATIVE; ANTINEOPLASTIC AGENT; QUINOLINE DERIVATIVE; TUBULIN MODULATOR;

ADVANCED CANCER; CANCER CELL; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SENSITIVITY; HISTOLOGY; HUMAN; INHIBITION KINETICS; LETTER; LITERATURE; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); METABOLISM;

ANTINEOPLASTIC AGENTS; HUMANS; PROTO-ONCOGENE PROTEINS C-MET; PYRROLIDINONES; QUINOLINES; TUBULIN MODULATORS;

EID: 84881242876     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1321     Document Type: Letter

References (5)

1. Basilico C, Pennacchietti S, Vigna E, Chiriaco C, Arena S, Bardelli A, et al. Tivantinib (ARQ 197) displays cytotoxic activity that is independent of its ability to bind MET. Clin Cancer Res 2013;19:2381-92.
2. Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Van Laethem JL, et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol 2013;14:55-63.
3. Sequist LV, von Pawel J, Garmey EG, Akerley WL, Brugger W, Ferrari D, et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 2011;29:3307-15.
4. Rodig S, Sequist LV, Schiller JH, Chen Y, Halim A, Waghorne C, et al. An exploratory biomarker analysis evaluating the effect of the c-MET inhibitor tivantinib (ARQ 197) and erlotinib in NSCLC patients in a randomized, double-blinded phase 2 study. Cancer Res 2012;72(Suppl 8):1729.
5. Katayama R, Aoyama A, Yamori T, Qi J, Oh-hara T, Song Y, et al. Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. Cancer Res 2013;73:3087-96.